Sagimet Biosciences
SGMT
66 hedge funds and large institutions have $78.8M invested in Sagimet Biosciences in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 13 closing their positions.
45% more capital invested
Capital invested by funds: $54.4M → $78.8M (+$24.3M)
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
5% more funds holding
Funds holding: 63 → 66 (+3)
7.03% less ownership
Funds ownership: 64.07% → 57.04% (-7%)
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
78% less call options, than puts
Call options by funds: $281K | Put options by funds: $1.26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.53M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$972K |
| 3 |
6CM
683 Capital Management
New York
|
+$700K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$435K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$423K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$2.66M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.39M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$2.17M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.9M |
| 5 |
BOCH
Blue Owl Capital Holdings
New York
|
-$1.77M |
SGMT Hedge Fund Activity: Q4 2024 in Review
66 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q4 2024, worth a combined $78.8M — up 45% from $54.4M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SGMT positions and 13 closed out — a net gain of 3 holders — while 15 added to existing stakes and 20 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.53M. The largest seller was Bank of America, cutting an estimated $2.66M.
- 66 institutional investors held Sagimet Biosciences (SGMT) as of Q4 2024, up from 63 in Q3 2024.
- Funds reported $78.8M of Sagimet Biosciences stock for Q4 2024, up 45% quarter-over-quarter.
- 16 funds opened new Sagimet Biosciences positions in Q4 2024 and 13 closed out, a net change of +3 holders.
- The largest Sagimet Biosciences buyer in Q4 2024 was Millennium Management, an estimated $2.53M added.
- The largest Sagimet Biosciences seller in Q4 2024 was Bank of America, an estimated $2.66M sold.
Based on aggregated 13F filings for Q4 2024.